港股异动 | 拨康视云-B(02592)跌超6%创新低宣布撤回CBT-009新药临床试验申请

智通财经03-20

智通财经APP获悉，拨康视云-B(02592)跌超6%，低见1.82港元刷新上市以来新低。截至发稿，跌6.09%，报1.85港元，成交额74.01万港元。消息面上，3月19日晚，拨康视云公告，称公司于2024年1月就CBT-009眼用乳液(一种以半氟化烷烃为基础的阿托品滴眼液，用于治疗青少年近视)可能在中国等地进行安慰剂对照多地区临床试验一事，与药审中心举行了新药临床试验申请前咨询会议。基于当时的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2620420690?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-20 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620420690","market":"us","top_or_hot":-1,"title":"港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，拨康视云-B(02592)跌超6%，低见1.82港元刷新上市以来新低。截至发稿，跌6.09%，报1.85港元，成交额74.01万港元。消息面上，3月19日晚，拨康视云公告，称公司于2024年1月就CBT-009眼用乳液(一种以半氟化烷烃为基础的阿托品滴眼液，用于治疗青少年近视)可能在中国等地进行安慰剂对照多地区临床试验一事，与药审中心举行了新药临床试验申请前咨询会议。基于当时的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416373.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 10:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1416373.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，拨康视云-B(02592)跌超6%，低见1.82港元刷新上市以来新低。截至发稿，跌6.09%，报1.85港元，成交额74.01万港元。消息面上，3月19日晚，拨康视云公告，称公司于2024年1月就CBT-009眼用乳液(一种以半氟化烷烃为基础的阿托品滴眼液，用于治疗青少年近视)可能在中国等地进行安慰剂对照多地区临床试验一事，与药审中心举行了新药临床试验申请前咨询会议。基于当时的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1416373.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CBT","symbol_name":"卡博特","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1416373.html","article_id":"2620420690","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620420690","pubTimestamp":1773974109,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，拨康视云-B跌超6%，低见1.82港元刷新上市以来新低。在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CBT":"卡博特","02592":"拨康视云-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4090":"商品化工","VXUS":"国际股票ETF-Vanguard"},"translate_title":"Changes in Hong Kong stocks | Diakangshiyun-B (02592) fell more than 6% to a new low and announced the withdrawal of CBT-009 new drug clinical trial application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1.5,"CBT":1.5,"02592":1.5},"content_text":"智通财经APP获悉，拨康视云-B(02592)跌超6%，低见1.82港元刷新上市以来新低。截至发稿，跌6.09%，报1.85港元，成交额74.01万港元。消息面上，3月19日晚，拨康视云公告，称公司于2024年1月就CBT-009眼用乳液(一种以半氟化烷烃为基础的阿托品滴眼液，用于治疗青少年近视)可能在中国等地进行安慰剂对照多地区临床试验一事，与药审中心举行了新药临床试验申请前咨询会议。基于当时的沟通情况，集团于2025年12月正式提交了新药临床试验申请，并于2026年1月获得受理。在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"executive,productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620420690","isCrawlerRequest":true}

港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请

精彩评论

港股异动 | 拨康视云-B(02592)跌超6%创新低宣布撤回CBT-009新药临床试验申请